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Abstract 
Despite some progress in recent years, the fight against parasitic diseases still remains a great 
challenge. Parasitic diseases affect primarily (but not exclusively) the poorest people living in 
underdeveloped regions of the world. The distribution of parasitoses are linked to tropical and 
subtropical climate conditions, to population growth and to impoverishment. If not treated, 
parasitic diseases may lead to serious health problems, and even death. Particularly vulnerable 
groups include infants and young children, pregnant women and immunocompromised 
individuals. Polyether ionophore antibiotics (ionophores), traditionally used in veterinary 
medicine as anti-coccidial feed additives and non-hormonal growth promoters, are of 
considerable interest, as they have been found to be highly effective agents against various 
parasites, both in vitro and in vivo. This review summarizes the anti-parasitic effects of the 
most important polyether ionophores against parasites that are responsible for a number of 
animal and human parasitic diseases. Recent findings and advances that support the potential 
of polyether ionophore antibiotics as novel anti-parasitic drug candidates are also presented 
and discussed. 
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1. Introduction  
Although parasites have accompanied mankind since the dawn of history [1], parasitic 
diseases are becoming an increasing human life and health concern, especially in the 
developing world [2–5]. Globally, parasitic diseases are responsible for almost one million 
deaths every year [6] which is nearly the same mortality rate caused by HIV/AIDS [7]. 
Infectious and parasitic diseases remain the major killers of children in low-income nations 
[8–10]. According to the World Health Organization (WHO), malaria, as the major parasitic 
disease killer, caused about 445,000 deaths in 2016, with many of those being in African 
children under the age of five [11]; it is however believed that many cases are undiagnosed 
and therefore unreported. 
 Parasites are distributed on all continents, but some latitudes are disproportionately 
more affected than others [12]. In tropical, subtropical and temperate regions, the combination 
of warm and humid climate with significant population growth and the accompanying 
poverty, contribute to the increased transmission of parasitic infections [3,5,12,13], most often 
by vectors such as mosquitos or ticks. Some parasites, like protozoans belonging to the 
Plasmodium group that are responsible for malaria, are a common cause of deaths worldwide 
[8,9], while others may lead to blindness, devastating neurological deficits, disfigurement and 
severe other disabilities and economic hardships [14–16]. Interestingly, among the 10 globally 
important tropical diseases, seven are parasitic ones, including African and American 
trypanosomiasis (sleeping sickness and Chagas disease, respectively), leishmaniasis, 
lymphatic filariasis, malaria, onchocerciasis and schistosomiasis [3]. 
Although parasitic diseases constitute a serious health problem for millions of people, 
especially in Africa, Latin America and Asia, many of the most common parasitic diseases are 
classified as neglected tropical diseases [17,18], and are comparatively less studied than other 
infectious diseases prevalent in high-income nations. In developed countries, protozoan 
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parasites more commonly cause gastrointestinal infections [12,19,20] than constitute the 
source of life-threatening infections, and for this reason, they raise relatively little interest in 
the scientific community. However, anybody who travels to endemic areas is at risk of 
contracting a parasitic disease and bringing it back home; such cases are known as “imported 
parasitic diseases” [21–23], and they represent a major obstacle in the effective elimination of 
several parasitoses. 
Another problem is that currently used anti-parasitic drugs have a number of 
limitations; they are difficult to administer, toxic, expensive and predominantly limited in 
scope, efficacy and/or availability [24–26]. Moreover, the phenomenon of drug resistance is 
spreading rapidly and many promising vaccines have not met expectations [27–29]. 
Therefore, there is an important need to focus on the discovery of novel, more effective and 
safer agents to control parasitic diseases. In this article, we show that polyether ionophore 
antibiotics (ionophores) and their derivatives are highly biologically active compounds, which 
should be considered as potential candidates for the development of new anti-parasitic 
chemotherapeutics.  
 
2. Structure of polyether ionophores  
Polyether ionophore antibiotics (Figure 1) are a group of more than 120 structurally 
characterized lipid-soluble compounds that consist of similar building blocks, share a 
common mode of action, and are produced by Gram(+) bacteria of the genus Streptomyces 
[30,31]. Functionally, the high anti-microbial bioactivity of ionophores (i.e. ion carriers) is 
strictly connected with their ionophoric properties. They have the ability to selectively bind 
metal cations, mainly alkali ones, and transport them from extracellular environment through 
biological membranes into cells [32–34], where the transported cation is released. As a result, 
the whole process disturbs the natural sodium/potassium concentration gradient (ion balance). 
4 
 
This leads to changes in the intracellular pH, to an increase in osmotic pressure, to formation 
of vacuoles within the cells (vacuolization), to mitochondrial injuries, to cell swelling by 
subsequent entry of water, and finally may result in cell death [35]. 
  
 
Figure 1. Structure of the most commonly used anti-coccidial polyether ionophore drugs that are incorporated in 
cattle and poultry feeds. 
 
Importantly, all ionophore antibiotics have common structural motifs (Figure 1). Their 
inner part is a hydrophilic polar cavity (pocket), which is formed not only by the ether oxygen 
atoms (usually as elements of tetrahydrofuran and/or tetrahydropyran rings), but also by the 
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oxygen atoms that belong to other functionally important groups, such as ketone and/or 
hydroxyl [35,36].  
The cation-binding selectivity (affinity) of ionophores is connected with their structure 
and the size of the polar pocket, inside which only the cations with strictly defined radii may 
be bound (Figure 2 and Table 1) [37–46]. Polyether ionophores may be classified as mono- 
or divalent ones if they are able to transport only monovalent cations or if besides monovalent 
cations, they have also the ability to transport divalent cations [47]. For example, lasalocid 
acid is recognized as a divalent ionophore as it shows a similar affinity for Cs+ and Ba2+ 
cations, while monensin is known as monovalent ionophore antibiotic because of its high 
affinity to Na+ cations (Figure 2 and Table 1) [41–46]. 
 
 
  
 
Figure 2. Structure of complexes of (A) lasalocid acid dimer with Ba2+, (B) monensin with Na+, (C) salinomycin 
with Na+ and (D) C(26) phenyl carbamate of monensin sodium salt (compound 8, Figure 5), which was 
determined using single-crystal X-ray diffraction method [37–40]. The hydrogen atoms and solvent molecules 
are omitted for clarity. 
A 
A B 
C D 
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Table 1. Selectivity of complexation of metal cations by polyether ionophores [41–46]. 
 
Polyether 
ionophore 
Selectivity of complexation of metal 
cations 
Ionomycin Ca2+ > Mg2+ >> Sr2+ ≈ Ba2+ 
Lasalocid acid 
Cs+ > Rb+ ≈ K+ > Na+ > Li+ 
Ba2+ > Sr2+ > Ca2+ > Mg2+ 
Monensin Na+ > K+ > Rb+ > Cs+ > Li+ 
Salinomycin K+ > Na+ > Cs+ > Sr2+ > Ca2+ ≈ Mg2+ 
Valinomycin Rb+ > K+ > Cs+ > Ag+ > Na+ > Li+ 
  
On the other hand, the outer part of ionophore antibiotic molecules comprises 
hydrophobic hydrocarbon skeletons with many methyl, ethyl and other non-polar groups 
(Figure 1). The presence of a hydrophobic surface guarantees high lipophilicity of the whole 
ionophore molecule, and thus facilitates its diffusion through cell membranes from the 
extracellular environment into target cells [35,36]. 
Among the numerous polyether ionophore antibiotics reported to date, there is a 
subgroup of nearly hundred compounds that act as freely mobile carriers across biological 
membranes. These biomolecules have been described as carboxylic ionophores, also known 
as nigericin antibiotics, in whose structure an additional terminal carboxyl group is present 
(Figure 1) that takes active part in the cation complexing process (Figure 2). Moreover, 
because of the presence of a carboxyl group at one end of the molecule and a hydroxyl 
group(s) at the other end, there is the possibility of the formation of a non-covalent link 
between both ends by intramolecular “head-to-tail” hydrogen bond(s), leading to a stable 
pseudocyclic conformation. Within such pseudocyclic structure, the selectively bound cation 
is completely enclosed in the polar cavity and shielded from the external environment (Figure 
2). Consequently, the bound cation can be effectively transferred into the interior of cells 
[48,49]. 
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3. Carboxylic ionophores – mechanism of cation transport 
Knowledge of the mechanism of cation transport realized by carboxylic ionophores is 
essential for both full understanding of the functioning of this subgroup of natural compounds 
and for explaining the broad spectrum of their biological properties. Mechanistically, 
carboxylic polyether ionophores transport cations in the form of host-guest complexes 
(Figure 2) through biological membranes in accordance with the one of the three different 
mechanisms described in literature (Figure 3) [48,49]. The particular mechanism depends on 
the cellular environment and the chemical structure of the ionophore. The transport can be 
realized (i) in the form of a neutral ionophore-cation complex (electroneutral transport 
mechanism), (ii) in the form of positively charged ionophore-cation complex, in which the 
carboxyl group of the ionophore is not chemically modified (electrogenic transport 
mechanism), or (iii) in the form of positively charged ionophore-cation complex, in which the 
carboxyl group of ionophore is chemically modified, for example, in the case of amide/ester 
analogues (bio-mimetic transport mechanism) (Figure 3) [48,49].  
 
 
 
Figure 3. Mechanisms of cations transport through biological membranes mediated by carboxylic polyether 
ionophores [48,49]. 
 
The bio-mimetic transport mechanism, being a type of electrogenic transport mode, 
involves the exchange of the metal cations of a pseudocyclic complex. Such complex is 
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formed between chemically modified polyether ionophore and guest cation at the one side of 
the lipid bilayer, and then diffuses across the biological membrane. At the opposite side, a 
cation-exchange process with counter-transported cation releases the guest cation. As a result, 
guest and counter-transported cations are transported through the lipid membrane in opposite 
directions (Figure 3) [48,49]. 
Since the driving force of the bio-mimetic transport mechanism is the concentration 
gradient of the counter-transported cations, a pH gradient is not required. Thus, it should be 
pointed out that the electroneutral transport is carried under neutral (inert) or basic conditions, 
because only under such conditions the carboxyl group of ionophore may undergo 
deprotonation [48,49]. On the other hand, electrogenic or bio-mimetic transport mechanism 
may be efficiently realized under non-basic conditions [48,49]. 
As a group of highly biologically active compounds, polyether ionophores show a 
broad spectrum of interesting pharmacological properties [35,50,51]. Some of these 
compounds have been used in veterinary medicine as non-hormonal growth promoters in 
ruminants because of their potent activity against various Gram(+) bacteria, and as agents to 
control the parasitic disease coccidiosis [35,51]. In addition, polyether ionophores have been 
shown to display activity against various human cancer cell lines and xenograft tumours. 
Moreover, anti-cancer activity of polyether ionophores have been demonstrated in a small 
group of cancer patients. They also have been shown to exhibit activity against multi-drug 
resistant cancer cells and cancer stem cells of different origin [52–54]. Importantly, in 
addition to the industrial use of ionophores in animal husbandry [55], some of them show 
anti-fungal, anti-viral, and anti-parasitic activity [35,51].  
 
4. Polyether ionophores – promising anti-parasitic drug candidates  
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Accumulating evidences clearly indicate that selected polyether ionophores and their 
semi-synthetic derivatives should be considered as potential agents in the development of 
effective drugs for the treatment of parasitic diseases [35,51]. For example, their effectiveness 
against parasites responsible for cryptosporidiosis, malaria, babesiosis, leishmaniasis, 
sarcocystosis and toxoplasmosis have been well documented in the scientific literature and 
will be presented in this review article. To the best of our knowledge, there is however no 
comprehensive review article in the scientific literature that would summarize the latest 
findings regarding the anti-parasitic activity of ionophores. Until now, the structures of more 
than one hundred polyether antibiotics have been determined, but only six carboxylic 
ionophores – lasalocid acid, maduramicin, monensin, narasin, salinomycin and semduramicin 
(Figure 1) – have been approved for use in veterinary practice (Table 2) [55]. 
 
Table 2. Ionophore-based anti-coccidial drugs used in cattle and poultry feeds [55]. 
 
Chemical name Trade name 
Lasalocid acid Avatec®, Bovatec® 
Maduramicin Cygro® 
Monensin Coban®, Coxidin®, Elancoban®, Rumensin® 
Narasin Maxiban®, Monteban® 
Salinomycin Biocox®, Sacox®, Salinomax® 
Semduramicin Aviax® 
  
Hence, in this review article the current status, recent progress and detailed discussion 
on the activity of the most promising carboxylic ionophores in the context of their potential 
use as novel and effective anti-parasitic agents are presented. 
 
4.1. Kinetoplastid diseases 
 Kinetoplastids are a group of flagellated protozoans that are distinguished by the 
presence of a DNA-containing region, known as a “kinetoplast”, in their single large 
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mitochondrion. Sleeping sickness (caused by human pathogenic subspecies of Trypanosoma 
brucei), Chagas disease (caused by Trypanosoma cruzi) and the leishmaniases (caused by 
Leishmania spp.) are the major human diseases caused by kinetoplastids. 
 
4.1.1. African trypanosomiasis  
African trypanosomiasis, also known as sleeping sickness in humans or nagana disease 
in livestock animals, is a parasitic disease, which is caused by protozoans of the genus 
Trypanosoma [56–58]. The parasites are transmitted to humans and animals by the bites of the 
tsetse flies (Glossina spp.), which are only found in sub-Saharan Africa [59,60]. Historically, 
African trypanosomiasis was a serious economic and public health problem, causing several 
epidemics in Africa over the last century [61]. According to the WHO, the estimated number 
of actual cases is below 20,000, but the estimated population at risk is still about 65 million 
people [62]. 
Depending on the species involved, the clinical signs in the first (haemo-lymphatic) 
stage may include intermittent fever, headache, joint and muscle pains, malaise, rash, weight 
loss and enlarged lymph nodes in the first few weeks to months of the infection [60,63]. 
Thereafter, the trypanosomes cross the blood-brain barrier and invade the central nervous 
system, causing mental deterioration, personality changes, partial paralysis and other 
neurological problems [60,63]. The characteristic feature of the infection that gave the disease 
its name, is daytime sleepiness with night-time sleep disturbance (night-time insomnia) that 
results in progressive confusion [64]. Unfortunately, if not efficiently treated, African 
trypanosomiasis may finally lead to death after few months or years [60,63]. 
As the few commonly used and outdated drugs available to treat sleeping sickness 
patients have limited efficacy as well as adverse side reactions, novel and better tolerated 
therapeutic strategies are highly desirable. The results from very recently published studies 
11 
 
have clearly shown that three carboxylic polyether ionophores – lasalocid acid, monensin and 
salinomycin (Figure 1) – are interesting lead compounds for rational anti-trypanosomal drug 
development in this context [65–67]. Importantly, it has been shown that monensin and 
salinomycin inhibit the growth of culture-adapted bloodstream forms of T. brucei (clone 427-
221a) in vitro at sub-micromolar concentration [66,67]. Although both ionophores have been 
shown to be less toxic to human cells (human myeloid leukemia HL-60 cells), their selectivity 
(cytotoxic to trypanocidal activity ratio) was only in a moderate range (GI50 ratio of 51 and 
2.4 for monensin and salinomycin, respectively, where GI50 ratios have been calculated using 
the formula GI50(HL-60)/GI50(T. brucei)) [66]. 
Mechanistically, the trypanocidal mode of action of ionophore antibiotics has been 
shown to be the result of an influx of Na+ resulting in an increased intracellular Na+ 
concentration followed by cell swelling (sodium influx-induced cell swelling) [67]. This 
mode of action differs from the mechanism of the anti-cancer activity of salinomycin reported 
to be the induction of apoptosis [53]. Interestingly, lasalocid acid has been found to induce a 
much faster cell swelling in trypanosomes than salinomycin and other polyether ionophores, 
and that the swelling was solely due to the influx of Na+ cations [65]. Thus, it has been 
suggested that lasalocid acid may be directly applicable for the treatment of nagana disease, 
particularly as it is used in cattle as medicated feed additive (Table 2) [65]. 
An attractive approach to improve the activity of lead compounds is their chemical 
modification as the resulting derivatives may show better biological activity. In the case of 
salinomycin and monensin, most of the tested derivatives were less active against 
trypanosomes than their corresponding parent compounds [66]. 
However, two salinomycin derivatives (Figure 4, compounds 12) obtained by 
chemical modification of its carboxyl group have been identified to display increased 
trypanocidal activity, with GI50 values in the mid nanomolar range and MIC values of < 1 
12 
 
μM. The obtained anti-trypanosomal activity is similar to those of suramin, one of the drugs 
used in the treatment of sleeping sickness [66]. Both these salinomycin derivatives (Figure 4, 
compounds 1‒2) have enhanced selectivity (GI50 ratio of 288 and 363 for 1 and 2, 
respectively), proving undoubtedly the huge therapeutic potential of such analogues [66]. On 
the other hand, none Mannich base derivatives of lasalocid acid displayed better trypanocidal 
activity and selectivity than the unmodified lasalocid acid [65]. 
 
 
Figure 4. Structure of salinomycin derivatives with potent anti-trypanosomal activity against bloodstream forms 
of T. brucei (clone 427-221a) (MIC and GI50 values in µM) [66]. 
 
4.1.2. Leishmaniasis  
Leishmaniasis is a vector-borne infection, which is caused by protozoans of the genus 
Leishmania [68,69]. The disease occurs worldwide in tropical and subtropical regions, and is 
transmitted to humans by the bite of infected female phlebotomine sandflies, mainly 
Phlebotomus and Lutzomyia [70]. There are about 20 different Leishmania species causing 
different forms of the diseases [71]. According to the WHO, between 700,000 to 1,000,000 
new cases of leishmaniasis occur annually and about 20,000 to 30,000 deaths, mainly in East 
Africa, South-East Asia and Latin America [72]. With respect to disease burden caused by 
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tropical infections, leishmaniasis ranks second in mortality and fourth in morbidity [73]. The 
incidence of leishmaniasis is linked to environmental changes and several risk factors, 
including deforestation, irrigation schemes, malnutrition, socioeconomic conditions and 
urbanization [74].  
Leishmaniasis causes a broad spectrum of clinical manifestations that strongly depend 
on the Leishmania species involved and the immune response of the host [75]. The symptoms 
of leishmaniasis are often skin sores (cutaneous and muco-cutaneous leishmaniasis) which 
erupt weeks to months after the infection, but also fever, low level of red blood cells as well 
as enlarged spleen and liver (visceral leishmaniasis) [76]. Moreover, co-infection with HIV 
may resulted in the developing of full-blown clinical disease, which is characterized by high 
rates of mortality [77]. 
Due to the different forms of leishmaniasis and the emergence of drug-resistant 
parasites, an efficient strategy of therapy of this disease remains a great challenge. Using both 
in vitro macrophage infection and ex vivo splenic explant models, monensin (Figure 1) was 
identified as one of the anti-leishmanial lead compounds against L. donovani with EC50 values 
of 0.23 µM (in vitro tests) and 0.85 µM (ex vivo tests) [78]. Because monensin demonstrated 
activity against L. donovani [78], the ionophore was also evaluated in vitro with L. major. 
Using the ex vivo lymph node system and macrophages infected with promastigotes of L. 
major, EC50 values for monensin were determined to be 0.09 µM and 0.38 µM, respectively 
[79]. In addition, two other carboxylic polyether antibiotics, narasin and salinomycin differing 
only in one methyl group at the C(4) position (Figure 1), inhibited the proliferation of L. 
donovani promastigotes at micromolar concentrations [80]. However, both ionophores 
displayed lower leishmanicidal activity compared to monensin, with EC50 values of 2.0 µM 
for narasin and 4.0 µM for salinomycin [80]. Yet, the low therapeutic index of salinomycin 
for Leishmania species precluding its clinical use as a leishmanicidal agent [80,81]. 
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4.2. Apicomplexan diseases 
 The Apicomplexa comprise a large phylum of obligate intracellular protozoan 
organisms that all have a parasitic lifestyle. This group is named after the apicopast, a 
vestigial plastid-like organelle present in most apicomplexans. The phylum Apicomplexa 
comprises over 5,000 species, many of which cause devastating diseases on a global scale. 
Human apicomplexan diseases include malaria, babesiosis, and toxoplasmosis, while 
coccidiosis is a common problem in livestock. 
 
4.2.1. Malaria  
Although great progress in the fight against malaria has been made since 2000, 
including significant reduction in mortality among children, it is still the most devastating 
parasitic disease globally, especially in sub-Saharan Africa [82]. In 2016, malaria infected 216 
million people worldwide and caused about 445,000 deaths [83]. Another problem is the 
emergence of malaria parasites resistant against several currently used anti-malarial drugs, 
including chloroquine, which constitutes a serious health threat in poor regions of the world 
[84,85]. Fortunately, polyether ionophores represent a very promising class of compounds 
with potent anti-plasmodial activity in the nano- and picomolar concentration range [81,86–
88]. 
Carboxylic ionophores, especially those that are specific to monovalent cations, have 
been reported as potent in vitro anti-malarial agents against various Plasmodium species 
[81,86–88], including P. berghei, P. falciparum, and P. yoelii, with IC50 values in the range of 
0.6–6.5 μg ml‒1 [81,86,88]. Similar degrees of effectiveness have been found in studies using 
animal models with ED50 values for in vivo anti-malarial activities varying between 0.4 and 
4.1 mg kg-1 against P. chabaudi and P. petteri [88,89]. Using P. petteri, monensin (Figure 1) 
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was identified as more effective anti-malarial agent in curing infected mice compared to 
nigericin (ED50 and ED90 values for monensin and nigericin were 1.1 and 3.5 mg kg
‒1 and 1.8 
and 4.6 mg kg‒1, respectively) [87]. Importantly, polyether ionophores have been reported to 
be 30,000-fold more potent in killing chloroquine-resistant malaria strains [51,87]. For 
example, 100% cure rates were obtained with monensin at doses of 10 mg kg–1 [87].   
The drug target profile for malaria elimination/eradication policy proposed by the 
Medicines for Malaria Venture suggests to focus on molecules which are active against both 
asexual and sexual life-cycle stages of malaria parasites [90,91]. Although most commonly 
used anti-plasmodial agents are ineffective against P. falciparum gametocytes (the sexual 
stages of the parasites responsible for transmission to the Anopheles vector), the carboxylic 
ionophores maduramicin and narasin (Figure 1) have been found to display potent 
gametocytocidal activity in low nanomolar concentrations [92]. Furthermore, maduramicin 
was shown to block completely malaria transmission in an in vivo rodent malaria model. 
Moreover, in combination with the pyrazolemaide PA21A050 (another promising anti-
malarial drug candidate), the gametocytocidal activity of maduramicin was significantly 
potentiated [92]. Encouragingly, the monovalent carboxylic ionophores monensin, nigericin 
and salinomycin (Figure 1) have been shown to kill efficiently both P. falciparum asexual 
parasites and gametocytes with IC50 values in the nanomolar concentration range, and have 
been therefore identified as potent transmission-blocking agents [90]. 
Considering the increasing problem of drug-resistance in malaria parasites against the 
most commonly used anti-malarial drugs [84,85], there is an urgent need to identify new 
molecules with potent anti-plasmodial activity. So far, a few studies on the action of 
ionophores towards both chloroquine-sensitive and chloroquine-resistant strains of P. 
falciparum had been carried out [86,93]. Some of the investigated polyether ionophores were 
shown to display anti-malarial activity against chloroquine-resistant strains with IC50 values 
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of 0.15–6.4 nM, demonstrating the great potential of certain ionophores in overcoming drug-
resistance [86,93]. Interestingly, monensin and salinomycin were more potent against 
chloroquine-resistant strains than commonly used drugs, including amodiaquine, artemether, 
artemisinin, artesumate, pyrimethamanine, trimethoprim or quinine [86,93]. Of note is that the 
polyether ionophores showed even higher activity towards chloroquine-resistant strains than 
towards chloroquine-sensitive ones [86].  
To improve the druggability and the therapeutic potential of polyether ionophores, 
development of various drug delivery systems that would be effective against drug-resistant 
strains of malaria parasites is a crucial need. In this context, a liposomal formulation loaded 
with the polyether antibiotic maduramicin was developed for the treatment of both 
chloroquine-sensitive and chloroquine-resistant Plasmodium infections. It was shown that 
liposome-based drug delivery of maduramicin enhanced its anti-malarial activity in vitro [94]. 
It was also found that delivery of monensin in PEGylated stearylamine liposomes increased 
the anti-malarial activity of the ionophore in vitro (liposomal monensin, IC50 = 0.74 nM; free 
monensin, IC50 = 3.17 nM) as well as in in vivo model systems without causing haemolysis of 
erythrocytes [95]. Importantly, liposomal monensin in combination with other anti-malarial 
drugs (e.g. chloroquine, FR900098 and piperaquine) showed additive to synergistic action 
towards P. falciparum and reduced the parasitic burden in P. berghei infected mice at 
comparable doses of anti-malarial drugs used alone [96]. Furthermore, it was found that 
monensin encapsulated in PLGA nanoparticles was about 10-fold more effective in impeding 
the growth of P. falciparum in culture compared to the free antibiotic [97]. 
To evaluate the anti-malarial therapeutic potential of ionophore antibiotics, the 
difference in the in vitro activity of the compounds between normal mammalian cells and 
malaria parasites (selectivity) is important to determine. It was shown that carboxylic 
ionophores can act in a very specific manner without any effects or morphological changes in 
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uninfected erythrocytes [81,98]. However, mammalian lymphoblasts and macrophages have 
been found to be affected by certain polyether ionophores at IC50 concentrations that are at 
least 35-fold higher than those determined against P. falciparum [81]. 
The anti-malarial activity of polyether antibiotics against blood-stage malaria parasites 
seems to be due to their ionophoric properties [87]. Na+ influx induced by these compounds is 
accompanied by an increase in intralysosomal pH (alkalinisation) which leads to inhibition of 
lysosomal haemoglobin degradation and finally to parasite cell death [87]. However, the 
possibility to treat selectively the trophozoite stage of P. falciparum using maduramicin (EC50 
value of 0.44 nM) has shed new light on the whole process [99]. Maduramicin, a sodium anti-
porter, is not likely to alter cytosolic pH but to increase the intracellular Na+ concentration 
(Na+ influx) through inhibition of the putative Na+ pump PfATP4 [99]. 
Of the semi-synthetic derivatives of polyether ionophores that have been tested for 
their anti-malarial activity, only some lasalocid acid and monensin analogues showed potent 
activity against selected Plasmodium species, including in vivo activity against P. berghei and 
P. chabaudi [87,100]. Six monensin carbamates (Figure 5, compounds 3–8) obtained by 
chemical modification of the hydroxyl group at the C(26) position showed in vivo anti-
plasmodial activity in mice experimental infected with malaria [100].  
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Figure 5. Structure of monensin derivatives with in vitro and in vivo anti-malarial activity surpassing that of the 
unmodified ionophore [100–102]. 
 
Chlorophenyl and phenyl carbamate derivatives of monensin (Figure 5, compounds 5 
and 8, respectively) were identified to be the most active analogues against P. berghei, with 
activities 40-times higher compared to the unmodified parent compound [100]. 
Encouragingly, some of the monensin derivatives (Figure 5, chlorophenyl carbamate 5, 
sulphonate 9 and carbonate 10) displayed higher in vitro activity against P. falciparum than 
monensin itself [101,102]. The increased anti-plasmodial activity has been linked to a 
significant change in the ionophoric properties of the modified compounds. Monensin 
derivatives preferentially complex and transport potassium over sodium and this inversion of 
complexation selectivity is probably the reason for the increased biological activity of 
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monensin semi-synthetic analogues [102]. To evaluate the therapeutic potential of monensin 
derivatives, the cytotoxicity of some analogues was also investigated [100]. Interestingly, the 
cytotoxicity of alkyl carbamates was significantly lower than that of unmodified monensin, 
while selected phenyl carbamates (Figure 5, compounds 3–5 and 7–8) displayed similar 
cytotoxicity than the parent compound [100]. The only exception was the bromophenyl 
carbamate derivative of monensin (Figure 5, compound 6), which was found to be about 
three times less toxic than the parent ionophore. In addition, this compound displayed activity 
against P. berghei in mice at a dose of 16 mg kg–1, whereas monensin was ineffective at 
dosages up to 100 mg kg–1 [100]. 
One of the derivatives of lasalocid acid, 5-bromolasalocid acid (Figure 6, compound 
11), was also found to have a better therapeutic index than the parent ionophore as it exhibits 
stronger interactions with lipid membranes [81,89]. Overall, the acceptable levels of toxicity 
and the good in vitro and in vivo therapeutic window are the major advantages of analogue 11 
(Figure 6) over unmodified lasalocid acid [81,89]. The group of polyether ionophore 
derivatives that show promise as basis for novel anti-malarial drug candidates should also 
include certain C(20)-amine analogues of salinomycin [103].  
 
 
 
Figure 6. Structure of 5-bromolasalocid acid with potent anti-malarial activity [81,89]. 
 
4.2.2. Babesiosis  
Babesiosis is an intraerythrocytic parasitic disease caused by malaria-like protozoans 
of the genus Babesia [104,105] and these pathogens are believed to be the second most 
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common blood parasites of mammals after trypanosomes [106]. Although more than 100 
Babesia species have been reported up to now, relatively few have been identified as human 
pathogens, including B. microti, B. divergens and B. duncani [107,108]. Transmission of 
babesiosis is via bites of infected ticks (e.g. Ixodes scapularis). The ticks can be found in 
forested areas, in dense brushes and grasslands. As they require warm weather conditions, 
they occur especially in southern regions of Europe and in the Northeast and upper Midwest 
parts of the United States. In the rest of the world, human babesiosis is found more 
sporadically [109]. In 2014, a total number of 1744 new cases of human babesiosis were 
reported in the United States [110].  
 Clinically, Babesia infections display a broad spectrum of disease severity, from 
asymptomatic to even life-threatening [107]. Although many individuals infected with 
Babesia do not show any symptoms, some may develop mild to moderate viral-like illness 
with the occurrence of arthralgia, chills, fever, loss of appetite and myalgia [111]. Because 
Babesia parasites infect and destroy red blood cells, babesiosis can cause a special type of 
anaemia, known as haemolytic anaemia, which may result in jaundice (yellowing of the skin) 
and dark urine [112]. 
 The cyclic polyether antibiotic valinomycin and carboxylic ionophore salinomycin 
(Figure 1) have been shown to exhibit potent in vitro anti-babesial activity against the related 
canine pathogen B. gibsoni [113]. Interestingly, depending on the type of red blood cells, both 
ionophores act in different ways [113]. In the case of the parasite infected erythrocytes 
containing low concentrations of potassium (which completely lack Na+/K+-ATPase activity), 
the ionophores did not affect the red blood cells (no changes in the intracellular 
concentrations of sodium, potassium and ATP, and no haemolysis was observed) but directly 
B. gibsoni, leading to the destruction of the pathogen [78]. On the other hand, if the parasite 
infected erythrocytes containing high concentrations of potassium (which contain Na+/K+-
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ATPase activity), the ionophores increased the intracellular sodium concentration and lowered 
the intracellular concentrations of potassium and ATP, which led to the lysis of the red blood 
cells and subsequently to the killing of B. gibsoni. However, the in vitro anti-babesial activity 
of both polyether antibiotics was significantly weaker on infected erythrocytes containing 
high concentrations of potassium, probably because of the protection by the Na+/K+-ATPase 
activity of the host cell [113]. Whether the results obtained with B. gibsoni can be also applied 
to human erythrocytes infected with Babesia species remains to be shown. 
 
4.2.3. Toxoplasmosis  
Toxoplasma gondii is probably the world’s most common protozoan parasites causing 
toxoplasmosis in animals and humans [114]. It can infect almost any cell from almost any 
warn-blooded animal but the final host are always domestic and wild cats, in which sexual 
reproduction takes place [115]. Humans contract toxoplasmosis by either ingesting vegetables 
or drinking water contaminated with oocysts, or by eating undercooked meat infected with the 
parasite [116]. T. gondii can also be congenitally transmitted from a mother to the developing 
foetus. 
Although more than 60 million people may be infected with T. gondii alone in the 
United States [117], only a small percentage of them would have experienced flu-like 
symptoms, because the immune system keeps the infection usually under control [118]. 
Infection with T. gondii during the first trimester of pregnancy may cause severe neurological 
damage in the developing foetus and can result in stillbirth. Toxoplasmosis is particularly 
dangerous for immunocompromised individuals, like patients with HIV/AIDS or organ 
transplant recipients under immunosuppressant medication [114,119–121]. In these patients, a 
previous existing toxoplasmosis cannot be anymore controlled by their immune system, 
leading to full-blown disease. 
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Usually, most healthy people do not need treatment for toxoplasmosis unless they 
show severe symptoms. In these cases of acute toxoplasmosis, patients can be treated with a 
co-therapy of pyrimethamine and sulfadiazine/clindamycin. Immunocompromised patients 
with toxoplasmosis need life-long chemotherapy. However, current anti-T. gondii 
chemotherapy is ineffective in the treatment of cerebral toxoplasmosis, a common 
complication in immunodeficient patients [51]. 
Of note is that polyether ionophore antibiotics have been shown to display activity 
against both tachyzoite and bradyzoite stages of T. gondii [122,123]. Monensin was found to 
inhibit the infectivity and viability of bradyzoites in vitro and in vivo [122]. Already at very 
low concentrations (0.001 µg ml‒1), monensin caused significant cytological changes in 
bradyzoites and induced swelling of the cells and the formation of large number of vacuoles 
in their cytoplasm [122]. Higher monensin concentrations led to lysis of bradyzoites [122]. 
These findings are consistent with results obtained from animal studies [124–126]. 
Prophylactic treatment of ewes with monensin was shown to reduce the neonatal mortality 
due to toxoplasmosis [126]. After administration of daily doses of monensin of 16.8 mg or 
27.9 mg, ewes had fewer abortions than untreated controls; lamb mortality was 16.7% in ewes 
fed with monensin compared to 55.2% in control ewes [126]. On the other hand, lasalocid 
acid (Figure 1) did not reduced the rate of abortion and neonatal mortality in sheep infected 
with T. gondii [125]. 
Mechanistically, it was shown that the toxoplasmicidal action of monensin is rapid and 
independent of the metabolic activity of the bradyzoites [127], and due to arresting T. gondii 
at an apparent late-S-phase cell cycle checkpoint [128]. Experiments with monensin-resistant 
T. gondii strains indicated that this effect of monensin is dependent on the function of a 
mitochondrial homologue of the MutS DNA damage repair enzyme TgMSH-1 [128]. 
Interestingly, the same TgMSH-1-dependent cell cycle arrest was also observed with 
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salinomycin [128]. Other mechanisms of toxoplasmicidal action of monensin, including the 
induction of autophagy and the initiation of marked morphological changes in the parasite’s 
mitochondria, have also been reported [129,130]. Remarkably, monensin was found not to 
induce autophagy in a parasite strains deficient in the mitochondrial DNA repair enzyme 
TgMSH-1 [130]. Thus, it was suggested that TgMSH-1 either mediates cell cycle arrest and 
autophagy independently, or autophagy occurs downstream of cell cycle arrest in a manner 
similar to apoptosis of cells arrested in G2 of the cell cycle [130]. 
 
4.2.4. Neosporosis  
Neosporosis is a disease caused by infection with Neospora caninum, which is often 
misidentified as Toxoplasma gondii because of structural, genetic and immunological 
similarities between the two protozoans [131,132]. Generally, neosporosis is an asymptomatic 
disease in adult animals, and for this reason, it is more frequently diagnosed in young animals 
[131]. Infection with the parasite leads to profound defects in the central nervous system and 
death, especially in dogs. Blindness, hepatitis (yellow eyes and skin), paralysis and respiratory 
failure are frequently observed symptoms as well [133,134]. In addition, neosporosis is a 
major cause of abortion in cattle and for high mortality rates in calves globally [135–137]. 
During an extensive screening study, a series of 43 different chemotherapeutics, 
including various anti-protozoal agents, dihydrofolate reductase/thymidylate synthase 
inhibitors, lincosamides, macrolides, pentamidine analogues, sulphonamides as well as six 
carboxylic polyether ionophores, were identified to display activity against N. caninum [138]. 
Noteworthy, five of the polyether antibiotics, namely lasalocid acid, maduramicin, monensin, 
narasin and salinomycin (Figure 1), showed 100% reduction in tachyzoite induced lesions at 
concentrations of about 10‒6 μg ml‒1 [51,138]. 
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4.2.5. Coccidiosis  
Coccidiosis is a parasitic disease that globally affects domestic animals [139]. The 
disease causes considerable economic losses in the poultry industry, but also in livestock 
farming of cattle, goats, pigs, rabbits and sheep [140,141]. The global economic losses from 
coccidiosis are estimated to be 3 billion $ per year [139]. 
Coccidiosis is usually an acute invasion and destruction of the intestinal epithelium 
and the underlying connective tissue of the mucosa caused by protozoans of the genus 
Eimeria, which results in diarrhoea, impaired feed conversion, and general weakness 
[142,143]. Other clinical signs include haemorrhage into the lumen of the intestine, catarrhal 
inflammation, emaciation, fever, inappetence, weight loss, poor growth, and in extreme cases, 
death of infected animals [55,144].  
In most countries, the preferred method for the control of coccidiosis involves adding 
appropriate anti-coccidial agents in the feed [145]. As already mentioned, polyether 
ionophores have found commercial use in veterinary medicine to improve feed metabolism in 
ruminants, but also as feed additive to control coccidiosis (Table 2). These prophylactic and 
therapeutic uses of polyether ionophores are the first approved applications of this group of 
compounds [146–148]. 
Monensin and salinomycin (Figure 1) in the form of their sodium salts are potent anti-
coccidial agents effective against various coccidiosis-causing parasites, including E. 
acervulina, E. brunette, E. maxima, E. necatrix and E. tenella [149–153]. Importantly, both 
carboxylic ionophores are more potent as anti-coccidial agents than many other commonly 
used drugs to treat coccidiosis [149–153]. Salinomycin effectively reduces mortality rates and 
leads to a notable increase in average body weight in infected chicken, compared to untreated 
infected controls [154].  
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Coccidiostatic tests of semduramicin (Figure 1) against a series of laboratory isolates 
of Eimeria species have clearly demonstrated the activity of this ionophore at concentrations 
ranging from 20 ppm to 30 ppm [155]. In another study, the activity of 13 anti-coccidials 
currently used in domestic poultry, including lasalocid acid, monensin, narasin (in 
combination with nicarbazin), salinomycin and semduramicin (alone or in combination with 
roxarsone) (Figure 1), were investigated to check whether the agents were effective at 
controlling E. lettyae-infections in the northern bobwhite (Colinus virginianus) [156]. 
Excellent to good efficacy (150 ppm) was found for the two ionophore antibiotics lasalocid 
acid and narasin in combination with nicarbazin, while only marginal protection of the birds 
were observed for monensin, salinomycin, and semduramicin alone or in combination with 
roxarsone [156]. Recently, lasalocid acid (120 ppm) and three other ionophores displayed 
moderate effectiveness in reducing lesions as well as improving weight gains in the chukar 
partridge (Alectoris chukar) infected with E. kofoidi or E. legionensis, or with both species 
together [157]. 
Clinically important is the often observed lethal interactions between certain 
ionophore anti-coccidials and the antibiotic tiamulin in chickens and turkeys. This 
incompatibility has been well established for monensin, narasin and salinomycin, and to a 
much lesser extent for maduramicin and semduramicin (Figure 1) [158]. In contrast, lasalocid 
acid seems to be compatible with tiamulin [158]. Although the nature of the interaction 
remains unknown, it has been suggested that tiamulin may reduce metabolic degradation and 
excretion of ionophores, leading to clinical signs of overdosage in animals [158]. This 
suggestion is in agreement with the observation that the same toxic signs (ataxia, locomotor 
disturbances, loss of appetite and neurotoxicity) have been seen after administration of the 
polyether antibiotics alone at high dosages or after co-treatment with tiamulin at standard 
usage levels [158]. 
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 Mechanistically, the coccidiocidal action of polyether ionophores involves disruption 
of ion transport across the cell membrane of the parasites [145], and is generally directed 
against sporozoites (the infectious life cycle stage of the parasites taken up by the host from 
the environment) and preventing them to infect intestinal host cells [145,159]. However, it is 
believed that the anti-coccidial action of the ionophores does not result in a complete 
prevention of infection but rather permits low levels of parasitaemia, thereby allowing some 
degree of immunity to develop within the host [55]. In addition to the effects against 
sporozoites, monensin has been found to be also effective against merozoites, the life-cycle 
stage forms that are released into the intestinal lumen after merogony in gut cells [145,160]. It 
has been suggested that the anti-coccidial activity of monensin may be due to blocking the 
development of trophozoites during merogony, which would reduce the proliferation of the 
parasites within the host [50,161,162]. 
 An interesting finding is the observation that certain carbamates of monensin (Figure 
7, compounds 12–14) were found to show higher in vivo anti-coccidial activity than the 
unmodified ionophore [100]. For example, halogenate phenylurethane derivatives of 
monensin displayed about two times higher coccidiostatic activity compared to the parent 
compound in chicks infected with E. tenella [100]. 
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Figure 7. Structure of monensin carbamates with potent in vivo anti-coccidial activity [100]. 
 
 A recently published patent related to novel monensin derivatives (Figure 8) describes 
the usage of these compounds for prevention, treatment or otherwise control of protozoans, 
including coccidia [163]. It has been demonstrated that compounds 15–18 (Figure 8) showed 
a significant activity towards E. tenella with very low cytotoxicities [163]. At relatively high 
concentrations, greater than or equal to 12.5 mg ml1, monensin lactone (Figure 8, compound 
15) appeared to inhibit significantly the development of E. tenella in cell culture by the 
inhibition of the formation of merozoites. Promisingly, also compound 16 (Figure 8) showed 
a very high efficacy against the parasite and was able to block the development of E. tenella 
in vitro, leading to the disappearance of schizonts and merozoites [163]. Importantly, at very 
low concentrations (lower than 0.39 mg ml1), compounds 17 and 18 (Figure 8) demonstrated 
significant efficacy against E. tenella as well [163].  
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Figure 8. The structure of monensin derivatives tested for their activity against E. tenella [163]. 
 
 The anti-coccidial action of C(20) salinomycin esters (Figure 9, compounds 19–26) 
has been assessed in chickens infected with E. tenella oocysts (5104 sporulated oocysts per 
bird) [164]. The compounds were mixed with the feed and given ad libitum. The anti-
coccidial effect was determined by parameters, such as lesion scores, morbidity due to the 
infection, average weight gain and reduction in oocyst release on days six and seven post 
infection compared to untreated infected controls [164]. At 60 ppm, salinomycin sodium salt 
exhibited the best anti-coccidial effect, whereas salinomycin potassium salt produced weight 
loss due to drug toxicity [164].  
 
 
Figure 9. C(20) salinomycin esters with potent anti-coccidial activity [164]. 
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 Among the unbranched O-acyl derivatives of salinomycin (Figure 9, compounds 19–
23) in their free acid form (X=H), a maximum activity was observed for compound 20, which 
was twice as active as salinomycin. In turn, the isobutyrate ester 24 (Figure 9) was about six 
times more active than salinomycin [164]. On the other hand, a decreased biological effect 
was observed for both dicarboxylic acid compounds 25 and 26 (Figure 9) [164]. The less 
pronounced activities of these derivatives might be explained by their hydrophilicity, which 
could disturb the transport through lipophilic cell membranes. The importance of evaluating 
counter ion effects (H+, Na+, K+) on the biological activity of the salinomycin derivatives was 
also demonstrated [164]. 
 
4.2.6 Cryptosporidiosis  
Cryptosporidiosis is a potentially severe and life-threating parasitic disease caused by 
protozoans of the genus Cryptosporidium [165,166]. Cryptosporidiosis in farm and wild 
animals is associated with weight loss and mortality, but may also cause zoonotic infections in 
humans [167–169]. It is one of the most common waterborne diseases in humans, and can be 
found worldwide in both recreational and drinking water [170]. The disease is transmitted by 
ingestion of food or water contaminated with oocysts shed by infected animals or humans, or 
by smear infections [171].  
The disease affects the distal small intestine and can also affect the respiratory tract, 
resulting in persistent watery diarrhoea with or without an unexplained cough, vomiting, 
dehydration, fatigue, nasal discharge, nausea, raised temperature, voice change and weight 
loss [172–175]. In both young children and immunosuppressed individuals, especially 
HIV/AIDS-positive and transplant patients, the symptoms are particularly severe and may 
lead to nutritional stunting and relatively high mortality rates, respectively [172–175]. Among 
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all identified species, C. hominis and C. parvum are responsible for more than 90% of human 
cases of cryptosporidiosis [176]. 
Some carboxylic polyether antibiotics have been shown to be highly active against C. 
parvum both in vitro and in vivo [177–186], among which maduramicin and monensin 
(Figure 1) were identified as the most active ones [177–180,183–186]. Monensin was found 
to impair parasite development in cell cultures in a dose-dependent manner. At 0.144 µM, 
monensin inhibited the development of the parasite by 98% without any detectable 
morphological alterations of the host cells [179]. These observations are consistent with other 
reported data showing that parasite development is completely inhibited by monensin at 0.134 
µM without any adverse effects to the host cells [178]. Maduramicin was shown to reduce the 
faecal parasite load by 96% [183]. 
Another study has shown a very potent synergistic effect of monensin in combination 
with the coccidiostatic agent toltrazuril against C. parvum oocysts; in combination, both 
agents were more effective than each of them alone [187]. In addition, monensin was found to 
display higher anti-cryptosporidial activity than toltrazuril at the same concentration [187]. 
Most new anti-cryptosporidial drug candidates for potential use in humans, including 
polyether ionophores, have been so far tested only in cell culture experiments [188,189]. 
However, a few polyether ionophores, including lasalocid acid and maduramicin (Figure 1), 
have been tested in a small number of patients with AIDS-related cryptosporidiosis, but 
unfortunately they failed to show any therapeutic effects [188]. 
Lasalocid acid has been reported to display anti-cryptosporidial activity both in vitro 
and in experimental-infected animals [190,191]. This includes studies that examined the 
effectiveness of lasalocid acid as novel agent against cryptosporidiosis in calves [190]. In 
addition, lasalocid acid was identified in a rat model as that agent that produced the highest 
anti-cryptosporidial effect among other chemotherapeutics tested [191]. 
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4.2.7. Sarcocystosis  
Sarcocystis species is a faecal-orally transmitted parasite of considerable veterinary 
economic and public health importance, which infects skeletal muscles of a wide-range of 
wild and domestic animals [192]. Moreover, this parasite may easily cross the blood-brain 
barrier, resulting in fatal inflammation of the brain and spinal cord (encephalomyelitis) [193]. 
Sarcocystis species require two hosts to complete their life cycle and humans can serve as the 
definitive host of the parasite [194]. Eating raw or undercooked beef and pork containing 
mature cysts of S. hominis or S. suihominis may lead to infection of humans with the parasites 
causing intestinal and muscular sarcocystosis [195,196]. 
For chemotherapy, the use of various anti-coccidials is usually recommended to treat 
sarcocystosis. Thus, carboxylic ionophores have been tried in a few instances to treat 
sarcocystosis in animals. For example, maduramicin (Figure 1) at a dose of 150 mg kg–1 
given orally to pups experimentally infected with Sarcocystis for 5 days starting from the day 
when sporocysts were found in the faeces for the first time, resulted in almost 97% reduction 
in sporocysts production [197,198]. Salinomycin (Figure 1) has been shown to prevent or to 
reduce acute sarcocystosis in some domestic animals [194,199,200]. At a dosage of 4 and 5 
mg kg–1, salinomycin was found to treat effectively experimental sarcocystosis in dogs and 
goats, respectively [197,201]. 
To date, it was assumed that polyether ionophore antibiotics should only be effective 
in treating intestinal stages of Sarcocystis during the acute phase [194], and should show no 
effect in treating acute muscular sarcocystosis. However, when animals were given 
salinomycin together with an infectious dose of Sarcocystis, the development of muscular 
sarcocystosis was prevented [200]. When lambs infected with S. tenella were treated for 29 
days with salinomycin, clinical sarcocystosis was reduced, but the completion of the life cycle 
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of some parasites was not fully blocked [200]. Encouragingly is the observation that when 
these lambs were challenged with 1 million of S. tenella sporocysts 63 days after the initial 
infection, they were found to have developed protective immunity [200]. 
 
4.3. Marine white spot disease  
Marine white spot disease, also known as saltwater ich or marine ich, is one of the 
most common and persistent diseases that infect cultured and wild marine fishes in home 
aquariums and aquaculture environments worldwide [202]. It is caused by an infection with 
Cryptocaryon irritans, a ciliated protozoan that is present in all saltwater environments 
[203,204]. This widespread protozoan penetrates the skin and gills of the fish, which, 
depending on the immune status of the affected host, may cause a wide spectrum of 
symptoms. In mild cases, the symptoms may just include a few pinhead-sized (0.5‒2.0 mm) 
white spots, nodules or patches, while in more severe cases they comprise irritation, lethargy, 
loss of appetite, disruption of osmoregulation and respiratory distress, and even death [205]. 
 Polyether ionophores have been identified as lead candidates for chemotherapy against 
cryptocaryoniasis as two of them, narasin and salinomycin (Figure 1), have been shown to 
kill C. irritans and to inhibit the growth of trophonts (adult, motile life-cycle stage of ciliate 
protozoans) both in vitro and in vivo [206]. In in vitro studies, it was found that narasin and 
salinomycin displayed high anti-parasitic activity at concentrations as low as 0.2 μM, while 
monensin (Figure 1) showed a direct killing effect on C. irritans at a higher concentration of 
2 μM [206]. During in vivo experiments, it was observed that fish that were fed a diet 
medicated with salinomycin survive longer than a control group on unmedicated diet [206]. 
 
4.4. Schistosomiasis  
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Schistosomiasis, also known as bilharzia, bilharziasis or snail fever, is an acute and 
chronic disease caused by parasitic flatworms (trematodes) of the genus Schistosoma 
[207,208]. Schistosomiasis is the second most devastating tropical disease in the world after 
malaria [209,210]. According to the WHO, the total number of people in need of preventive 
chemotherapy for schistosomiasis was 207.7 million in 2016, of which 111.8 million were 
school-aged children, especially those from developing countries in Africa, Asia, South 
America and the Caribbean region [211].  
People usually acquire schistosomiasis when they come in contact with fresh water 
contaminated with the larval forms of the parasite [211,212]. Symptoms include abdominal 
pain, bloody stool, haematuria (blood in the urine) and diarrhoea [212,213]. After a few 
weeks from the initial infection, acute schistosomiasis (Katayama fever) may occur. The 
typical symptoms of acute schistosomiasis include fever, urticarial, enlarged liver and spleen, 
and bronchospasm [214]. In children, who are especially vulnerable to bilharzia, it may cause 
poor growth and learning difficulty as well [215,216]. 
It has been shown that the polyether ionophore lasalocid acid (Figure 1) possesses 
great promise as potential schistosomacidal agent. At a dosage of 100 mg kg–1, lasalocid acid 
was found to decrease significantly the worm burden (female worms, 41%; male worms, 
44%) in in vivo studies compared to controls [217]. In addition, the ionophore also improved 
the organ pathology and was well tolerated by mice infected with the parasite [217]. For 
salinomycin (Figure 1), results from in vitro studies indicated a rather weak response (IC50 = 
32.6 µM) against schistosomula, the immature form of the parasite in humans [218]. 
 
5. Conclusions  
The best way to control effectively any parasitic disease is to improve the living 
standards of people living in underdeveloped countries by raising economic growth. However, 
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it is not an easy task and requires substantial financial investments. Parasitic diseases have 
considerable effects on both the economy and public health, and many parasitoses cause more 
morbidity than mortality. In children, parasitic diseases can cause anaemia, stunting and 
learning difficulties, although most of these effects are usually reversible with treatment. 
Early diagnosis of individuals with any parasitic disease is very important in order to prevent 
any complications. Due to the lack of vaccines, effective chemotherapies are crucial to treat 
successfully patients affected by parasitic diseases. Unfortunately, most commonly used anti-
parasitic drugs are outdated and show problems with toxicity. In addition, the large-scale and 
long-term use of key drugs has led to the development of drug-resistant parasites. Therefore, 
the search for new generation, highly active and tolerable anti-parasitic agents is of pivotal 
importance in the fight against parasitic diseases. 
 Research over the last years have indicated that polyether ionophore antibiotics and 
their derivatives are promising anti-parasitic drug candidates. Of particular interest are six 
ionophores, namely lasalocid acid, maduramicin, monensin, narasin, salinomycin and 
semduramicin, as they are widely used in veterinary sector as non-hormonal growth 
promoters and anti-coccidial medicines. In addition to their industrial use, these polyether 
ionophores have been shown to display promising activity against a variety of parasites, 
including trypanosomiasis, leishmaniasis, malaria, babesiosis, cryptosporidiosis, 
toxoplasmosis, and schistosomiasis (Table 3). 
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Table 3. Summary of the anti-parasitic activity of carboxylic polyether ionophores. 
Parasitic 
disease 
Disease 
Polyether 
ionophore 
Kinetoplastid 
diseases 
African 
trypanosomiasis 
lasalocid acid 
monensin 
salinomycin 
Leishmaniasis 
monensin 
narasin 
salinomycin 
Apicomplexan 
diseases 
Malaria 
lasalocid acid 
maduramicin 
monensin 
narasin 
salinomycin 
Coccidiosis 
lasalocid acid 
maduramicin 
monensin 
narasin 
salinomycin 
semduramicin 
Babesiosis salinomycin 
Toxoplasmosis 
lasalocid acid 
monensin 
Neosporosis 
lasalocid acid 
maduramicin 
monensin 
narasin 
salinomycin 
Cryptosporidiosis 
lasalocid acid 
maduramicin 
monensin 
Sarcocystosis 
maduramicin 
salinomycin 
Neosporosis 
lasalocid acid 
maduramicin 
monensin 
narasin 
salinomycin 
 
Marine white spot 
disease 
narasin 
salinomycin 
 Schistosomiasis 
lasalocid acid 
salinomycin 
 
  
 Some derivatives of these ionophores show even better anti-parasitic activities 
compared to their unmodified parent compounds. The increased efficiency and selectivity 
36 
 
demonstrated for some polyether ionophore derivatives against various parasites, including 
trypanosomes and apicomplexans, clearly indicates the huge potential of this group of 
compounds, which should provide innovative ideas for the rational development of new 
analogues in the coming years. 
 
Dedication  
We would like to dedicate this article to Professor Bogumił Brzezinski in honour of his 75th 
birthday. 
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